Core Insights - The article highlights the advancements of Shenzhen-based Jingfeng Medical in the field of surgical robotics, emphasizing its role in transforming China from a follower to a leader in high-end medical technology [1][5] Group 1: Technological Advancements - Jingfeng Medical has developed multiple surgical robot technologies, including multi-port, single-port, and natural orifice surgery robots, marking a significant achievement in the industry [1][2] - The company's multi-port laparoscopic surgical robot received CE certification in March, allowing it to enter the European medical device market, which has been dominated by foreign products [2][3] - Jingfeng Medical has independently mastered core technologies such as structural design, system control, motion algorithms, and artificial intelligence algorithms [2] Group 2: Clinical Achievements - The multi-port laparoscopic surgical robot has completed over 8,000 clinical surgeries globally, while the single-port version has surpassed 1,000 surgeries [2] - In November 2024, Jingfeng Medical successfully completed the world's first remote surgery using a single-arm single-port robot, demonstrating its innovative capabilities [2] Group 3: Global Expansion - Jingfeng Medical has established strategic partnerships with global leaders to expand into the European market, targeting over 30 key countries and regions for localized sales and support [3] - Since the start of 2025, the company has secured 25 commercial orders in nearly 20 countries within just seven months, indicating a rapid acceleration in its internationalization efforts [3] Group 4: Collaborative Innovation - The company has received regulatory approval for its bronchoscopic robot, CP1000, and has initiated clinical trials for laparoscopic and gynecological robots in Shenzhen [4] - Jingfeng Medical collaborates with local hospitals to create real-world testing environments for its products, enhancing innovation and data accumulation [4]